MCID: NLD001
MIFTS: 50

Nail Disease

Categories: Skin diseases, Rare diseases, Genetic diseases, Fetal diseases

Aliases & Classifications for Nail Disease

Summaries for Nail Disease

MedlinePlus : 43 Your toenails and fingernails protect the tissues of your toes and fingers. They are made up of layers of a hardened protein called keratin, which is also in your hair and skin. The health of your nails can be a clue to your overall health. Healthy nails are usually smooth and consistent in color. Specific types of nail discoloration and changes in growth rate can be signs of lung, heart, kidney, and liver diseases, as well as diabetes and anemia. White spots and vertical ridges are harmless. Nail problems that sometimes require treatment include Bacterial and fungal infections Ingrown nails Tumors Warts Keeping your nails clean, dry, and trimmed can help you avoid some problems. Do not remove the cuticle, which can cause infection.

MalaCards based summary : Nail Disease, also known as nail diseases, is related to paronychia and tooth agenesis, selective, 4, and has symptoms including exanthema, pruritus and clubbing of nail. An important gene associated with Nail Disease is FZD6 (Frizzled Class Receptor 6), and among its related pathways/superpathways are Proteoglycans in cancer and Colorectal Cancer Metastasis. The drugs Chlorhexidine and Ethanol have been mentioned in the context of this disorder. Affiliated tissues include nail, skin and lung, and related phenotype is shRNA abundance <= 50%.

Disease Ontology : 12 An integumentary system disease that is located in nail.

Wikipedia : 76 A nail disease or onychosis is a disease or deformity of the nail. Although the nail is a structure... more...

Related Diseases for Nail Disease

Diseases in the Nail Disease family:

Nail Disorder, Nonsyndromic Congenital, 6 Nail Disorder, Nonsyndromic Congenital, 2
Nail Disorder, Nonsyndromic Congenital, 3 Nail Disorder, Nonsyndromic Congenital, 1
Nail Disorder, Nonsyndromic Congenital, 5 Nail Disorder, Nonsyndromic Congenital, 4
Nail Disorder, Nonsyndromic Congenital, 7 Nail Disorder, Nonsyndromic Congenital, 8
Nail Disorder, Nonsyndromic Congenital, 9 Nail Disorder, Nonsyndromic Congenital, 10

Diseases related to Nail Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 30)
# Related Disease Score Top Affiliating Genes
1 paronychia 31.3 EGFR KRAS
2 tooth agenesis, selective, 4 10.6
3 nail-patella syndrome 10.6
4 keratosis palmoplantaris striata ii 10.6
5 bronchiolo-alveolar adenocarcinoma 10.1 EGFR KRAS
6 pulmonary blastoma 10.1 EGFR KRAS
7 lung adenoid cystic carcinoma 10.0 EGFR KRAS
8 acneiform dermatitis 10.0 EGFR KRAS
9 psoriatic arthritis 10.0
10 arthritis 10.0
11 adenosquamous cell lung carcinoma 10.0 EGFR KRAS
12 psoriasis 10.0
13 mucinous adenocarcinoma 10.0 EGFR KRAS
14 small intestinal adenocarcinoma 9.9 EGFR KRAS
15 nail disorder, nonsyndromic congenital, 10 9.9
16 lung benign neoplasm 9.9 EGFR KRAS
17 malignant ovarian surface epithelial-stromal neoplasm 9.8 EGFR KRAS
18 enthesopathy 9.7
19 ovary epithelial cancer 9.7 EGFR KRAS
20 anal canal adenocarcinoma 9.6 KRAS TNFRSF1B
21 cleft palate, isolated 9.5
22 pemphigus vulgaris, familial 9.5
23 pemphigus vulgaris 9.5
24 lymphoma 9.5
25 dermatophytosis 9.5
26 pemphigus 9.5
27 cleft lip 9.5
28 adenosquamous carcinoma 9.4 EGFR KRAS
29 exanthem 9.1 EGFR KRAS TNFRSF1B
30 nail disorder, nonsyndromic congenital, 4 8.7 CEP76 ESCO1 RSPO4 TUBB6 ZNF519

Graphical network of the top 20 diseases related to Nail Disease:



Diseases related to Nail Disease

Symptoms & Phenotypes for Nail Disease

UMLS symptoms related to Nail Disease:


exanthema, pruritus, clubbing of nail

GenomeRNAi Phenotypes related to Nail Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 shRNA abundance <= 50% GR00343-S 9.17 EGFR FZD6 KRAS PLCD1 POGZ TNFRSF1B

Drugs & Therapeutics for Nail Disease

Drugs for Nail Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
2
Ethanol Approved Phase 4 64-17-5 702
3
Phenol Approved, Experimental Phase 4,Not Applicable 108-95-2 996
4
Amorolfine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 78613-35-1
5
Ciclopirox Approved, Investigational Phase 4,Phase 3,Phase 2 29342-05-0 2749
6
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
7
Bifonazole Approved, Investigational Phase 4,Phase 3,Not Applicable 60628-96-8 2378
8
Terbinafine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 91161-71-6 5402 1549008
9
Etanercept Approved, Investigational Phase 4 185243-69-0
10
Docetaxel Approved, Investigational Phase 4,Phase 3,Not Applicable 114977-28-5 148124
11
Lenograstim Approved, Investigational Phase 4 135968-09-1
12
Tavaborole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 174671-46-6
13
Itraconazole Approved, Investigational Phase 4,Phase 3,Phase 2 84625-61-6 55283
14
Apremilast Approved, Investigational Phase 4,Phase 2 608141-41-9 11561674
15
Efinaconazole Approved Phase 4,Phase 3,Not Applicable 164650-44-6
16
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
18
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
19
Nicotinamide Approved, Investigational, Nutraceutical Phase 4 98-92-0 936
20 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Anti-Infective Agents, Local Phase 4,Not Applicable
22 Central Nervous System Depressants Phase 4
23 Chlorhexidine gluconate Phase 4
24 Dermatologic Agents Phase 4,Phase 2,Not Applicable
25 Disinfectants Phase 4
26 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
29 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Keratolytic Agents Phase 4,Not Applicable
35 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Peripheral Nervous System Agents Phase 4,Phase 2
37 Polyhexamethylene biguanide Phase 4
38 Analgesics Phase 4,Phase 2
39 Analgesics, Non-Narcotic Phase 4,Phase 2
40 Anti-Inflammatory Agents Phase 4,Phase 2
41 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2
42 Antirheumatic Agents Phase 4,Phase 2
43 Gastrointestinal Agents Phase 4,Phase 2
44 Immunosuppressive Agents Phase 4,Phase 2,Phase 1
45 Adjuvants, Immunologic Phase 4
46 Antimitotic Agents Phase 4,Phase 3
47
Hydroxyitraconazole Phase 4,Phase 3,Phase 2
48 Micronutrients Phase 4
49 Nicotinic Acids Phase 4
50 Trace Elements Phase 4

Interventional clinical trials:

(show top 50) (show all 139)
# Name Status NCT ID Phase Drugs
1 Effectiveness of Lavage With Alcohol - Chlorhexidine for Chemical Matricectomy Unknown status NCT01844141 Phase 4 70% alcohol;70% alcohol - 0.5% clorhexidine
2 Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis Unknown status NCT01014637 Phase 4 Amorolfine (Antifungal);RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)
3 Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis Unknown status NCT02436291 Phase 4
4 Efficacy of Intraoperative Surgical Scrubbing in Reducing Bacterial Load After Nail Removal Surgery Completed NCT01330706 Phase 4 Polihexanide
5 Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis Completed NCT00581100 Phase 4 etanercept
6 A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen Completed NCT01107756 Phase 4 LENOGRASTIM (GRANOGYTE 34)
7 An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents Completed NCT03405818 Phase 4 Tavaborole 5% Topical Solution
8 Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus a Two-course Treatment With Urea 40% Ointment and Bifonazole Cream 1% Completed NCT02705664 Phase 4 Loceryl Nail Lacquer;Urea Ointment;Bifonazole Cream
9 Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus Ciclopirox Nail Lacquer Completed NCT02679911 Phase 4 Loceryl Nail Lacquer;Ciclopirox Nail Lacquer
10 A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment Completed NCT02464826 Phase 4 Nailprotex
11 Antifungal Activity of Loceryl Nail Lacquer in Combination With a Cosmetic Varnish Completed NCT02321098 Phase 4 Loceryl Nail Lacquer;Loceryl Nail Lacquer;Loceryl Nail Lacquer follow up period
12 Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis Completed NCT01851590 Phase 4 Amorolfine;Terbinafine
13 Topical Penlac Nail Lacquer for Onychomycosis in Children Completed NCT01419847 Phase 4 Ciclopirox;Placebo
14 Scoring Clinical Index For Onychomycosis in Toenail Onychomycosis Treating With Itraconazole Capsules Completed NCT00871728 Phase 4 Itraconazole
15 Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis Recruiting NCT03280927 Phase 4 Jublia®
16 Comparison Between Long-pulsed Nd:YAG, Amorolfine and Combination Treatment in Treating Non-dermatophyte Onychomycosis Recruiting NCT02812043 Phase 4 Amorolfine
17 Study Evaluating the Effect of Jublia on Dermatophytomas Active, not recruiting NCT03098615 Phase 4 Jublia (Efinaconazole 10% Topical Solution)
18 Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish Active, not recruiting NCT03110029 Phase 4 Efinaconazole 10% (Jublia)
19 Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis Active, not recruiting NCT02812771 Phase 4 Efinaconazole
20 An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis Enrolling by invitation NCT03022617 Phase 4 Apremilast
21 Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic Nail Disease Not yet recruiting NCT03263624 Phase 4 Tazarotene Cream 0.1%
22 TDT 067 Onychomycosis Study Unknown status NCT01145807 Phase 3 TDT067;Placebo;Transfersome
23 Treating Onychomychosis Unknown status NCT00776464 Phase 2, Phase 3
24 Evaluation of the Cryotherapy in the Prevention of Nails Toxicity Induced by Taxotere® in Breast or Prostate Cancer Completed NCT00925418 Phase 3
25 Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail. Completed NCT00356915 Phase 3 Itraconazole 100mg capsules;Itraconazole 200mg tablets;Placebo tablets
26 Evaluation of the Efficacy and Safety of Indigo Naturalis Oil Extract on Psoriatic Nails Completed NCT00999687 Phase 2, Phase 3 Indigo Naturalis Extract in Oil
27 Clinical Trial on Onychomycosis With P-3058 Nail Solution in Pediatric Population Completed NCT02547701 Phase 3 P-3058
28 Safety and Efficacy of Luliconazole Solution, 10% in Subjects With Mild to Moderate Onychomycosis Completed NCT01431820 Phase 2, Phase 3 Luliconazole Solution, 10%;Vehicle Solution
29 Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail Completed NCT01302119 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
30 Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail Completed NCT01270971 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
31 Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis Completed NCT01008033 Phase 3 IDP-108;Vehicle
32 The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis Completed NCT01007708 Phase 3 IDP-108;Vehicle
33 PinPointe FootLaser for the Treatment of Onychomycosis Completed NCT00935649 Phase 2, Phase 3
34 Comparative Efficacy of Bifonazole Cream vs Placebo After Nail Ablation With Urea Paste Completed NCT00781820 Phase 3 Bifonazole cream 1%;Placebo cream
35 Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00459537 Phase 3 terbinafine hydrogen chloride;amorolfine nail lacquer
36 Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail Completed NCT00443898 Phase 3 terbinafine;Placebo;terbinafine;Placebo
37 Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail Completed NCT00443820 Phase 3 terbinafine;Placebo;terbinafine;Placebo
38 Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients Recruiting NCT03168841 Phase 3 Efinaconazole Topical
39 Study to Evaluate the Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO) Recruiting NCT02866032 Phase 3 MOB015B;Ciclopirox 80 mg/g
40 A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO) Recruiting NCT02859519 Phase 3 MOB015B;MOB015B Vehicle
41 Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Toenail Onychomycosis Active, not recruiting NCT02549001 Phase 3 P-3058 10%;vehicle of P-3058 10%;amorolfine 5%
42 Antifungal Drugs in Treatment of Onychomycosis Not yet recruiting NCT03171584 Phase 3 Terbinafine
43 Study Efficacy and Safety in Comparative Use of Investigational Product Adjuvant Treatment in Onychomycosis Not yet recruiting NCT02961634 Phase 3 Ciclopirox 8%
44 Safety & Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails Terminated NCT01208168 Phase 3 NAB001;Vehicle alone
45 Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails Terminated NCT01208129 Phase 3 NAB001;Placebo control
46 Study to Evaluate the Efficacy and Safety of P-3058 Nail Solution in the Treatment of Onychomycosis Withdrawn NCT03094468 Phase 3 P-3058 (terbinafine hydrochloride 10%);Vehicle of P-3058
47 Erbium-doped Yttrium Aluminium Garnet Laser(Er:Yag)Associated With Amorolfine Lacquer in the Treatment of Onychomycosis Unknown status NCT01528813 Phase 2 Amorolfine lacquer
48 Using Light Therapy to Treat Toe Nail Fungus Unknown status NCT00771732 Phase 2
49 Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia Congenita Unknown status NCT00936533 Phase 2 Dysport® (Botulinumtoxin A (Btx A));Placebo
50 A Trial of the Safety and Efficacy of EcoNail™ in the Treatment of Fungus Infections of the Great Toenail Unknown status NCT00385502 Phase 2 EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)

Search NIH Clinical Center for Nail Disease

Cochrane evidence based reviews: nail diseases

Genetic Tests for Nail Disease

Genetic tests related to Nail Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Nail 29

Anatomical Context for Nail Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Nail Disease:

19
Nail

MalaCards organs/tissues related to Nail Disease:

41
Skin, Lung, Kidney, Liver, Heart, Testes, Prostate

Publications for Nail Disease

Articles related to Nail Disease:

(show top 50) (show all 60)
# Title Authors Year
1
MRI of psoriatic nail disease pre- and post-TNF inhibitor therapy shows persistent subclinical inflammation after 6 months despite good clinical response. ( 29531786 )
2018
2
The microvascular and morphostructural changes of nails in psoriatic patients with nail disease; a link between ultrasound and videocapillaroscopy findings in the nailfold. ( 29730685 )
2018
3
The microbial flora of taxane therapy-associated nail disease in cancer patients. ( 29447679 )
2018
4
Rare Variant of Ankyloblepharon-ectodermal Defect-cleft Lip/Cleft Palate Syndrome: Curly Hair-ankyloblepharon-nail Disease Syndrome. ( 29440852 )
2018
5
Reply to: &amp;quot;The microbial flora of taxane therapy-associated nail disease in cancer patients&amp;quot;. ( 29447686 )
2018
6
Biotin for the treatment of nail disease: what is the evidence? ( 29057689 )
2017
7
Detection of subclinical ultrasound enthesopathy and nail disease in patients at risk of psoriatic arthritis. ( 27932277 )
2016
8
Nail Disease for the Primary Care Provider. ( 26476249 )
2015
9
Optimal management of nail disease in patients with psoriasis. ( 29387579 )
2015
10
Ultrasound in the management of nail disease. ( 26895940 )
2015
11
Psoriatic nail disease, a predictor of psoriatic arthritis. ( 25409998 )
2014
12
Potential use of optical coherence tomography and high-frequency ultrasound for the assessment of nail disease in psoriasis and psoriatic arthritis. ( 23988587 )
2013
13
Drug-related nail disease. ( 24079591 )
2013
14
Metoprolol-induced psoriatic nail disease. ( 22724586 )
2013
15
Efficacy of pulsed dye laser plus topical tazarotene versus topical tazarotene alone in psoriatic nail disease: a single-blind, intrapatient left-to-right controlled study. ( 23423871 )
2013
16
Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. ( 24117389 )
2013
17
Assessment of psoriatic nail disease activity by rheumatologists: comment on the article by Lubrano et al. ( 22623218 )
2012
18
Patient assessments of skin, joint, and nail disease activity in psoriatic arthritis. ( 22383354 )
2012
19
Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails. ( 22156725 )
2012
20
Nail disease in psoriatic arthritis: distal phalangeal bone edema detected by magnetic resonance imaging predicts development of onycholysis and hyperkeratosis. ( 22337245 )
2012
21
Optical coherence tomography: a new tool to assess nail disease in psoriasis? ( 21791896 )
2011
22
Nutrition and nail disease. ( 20620759 )
2010
23
Evaluation of nail disease in psoriatic arthritis by using a modified nail psoriasis severity score index. ( 21174373 )
2010
24
Clinical practice. Fungal nail disease. ( 19439745 )
2009
25
Psoriatic nail disease: quality of life and treatment. ( 19799826 )
2009
26
The pathogenesis of psoriatic arthritis and associated nail disease: not autoimmune after all? ( 19424069 )
2009
27
Nail disease in pemphigus vulgaris. ( 19903430 )
2009
28
Management of psoriatic nail disease. ( 19341941 )
2009
29
Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. ( 18083272 )
2008
30
Therapies for psoriatic nail disease. A systematic review. ( 16724366 )
2006
31
Alefacept treatment of psoriatic nail disease: how severe should nail psoriasis be? ( 16546613 )
2006
32
Alefacept in the treatment of psoriatic nail disease: a proof of concept study. ( 16673801 )
2006
33
Alefacept in the treatment of psoriatic nail disease: a small case series. ( 15928640 )
2005
34
Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. ( 18360572 )
2005
35
Molecular genetics of hereditary hair and nail disease. ( 15468149 )
2004
36
Extended report: nail disease in psoriatic arthritis--clinically important, potentially treatable and often overlooked. ( 15113998 )
2004
37
One interpretation of a psychometric study of patients with nail disease. ( 12664041 )
2003
38
Observer agreement in recording the clinical signs of nail disease and the accuracy of a clinical diagnosis of fungal and non-fungal nail disease. ( 12653750 )
2003
39
Recurrence of fungal nail disease and the dissociation of relapse from re-infection. ( 11501665 )
2001
40
Psoriatic arthritis, nail disease and pustules following Hodgkin's lymphoma. ( 10952760 )
2000
41
Nail disease: antifungals have similar cure rates, different side-effects. ( 10570567 )
1999
42
Manual of nail disease and surgery ( 9767626 )
1998
43
Itraconazole now indicated to treat fungal nail disease. ( 11361668 )
1996
44
Fungal nail disease: a guide to good practice (report of a Working Group of the British Society for Medical Mycology). ( 7496239 )
1995
45
The differential diagnosis of nail disease. ( 11361432 )
1995
46
Pediatric nail disease. ( 7742236 )
1995
47
Oral therapeutic agents in fungal nail disease. ( 8077514 )
1994
48
Epidemiology of fungal skin and nail disease: roundtable discussion held at Dermatology 2000, Vienna, 17 May 1993. ( 8186144 )
1994
49
Lamisil -- A New Measure in Antifungal Therapy in Skin and Nail Disease. Proceedings of a symposium. Vienna, Austria, 18 May 1993. ( 7910478 )
1994
50
The spectrum of nail disease in patients with human immunodeficiency virus infection. ( 1619083 )
1992

Variations for Nail Disease

ClinVar genetic disease variations for Nail Disease:

6
(show all 13)
# Gene Variation Type Significance SNP ID Assembly Location
1 FZD6 NM_003506.3(FZD6): c.1750G> T (p.Glu584Ter) single nucleotide variant Pathogenic rs151339002 GRCh37 Chromosome 8, 104342091: 104342091
2 FZD6 NM_003506.3(FZD6): c.1750G> T (p.Glu584Ter) single nucleotide variant Pathogenic rs151339002 GRCh38 Chromosome 8, 103329863: 103329863
3 FZD6 NM_003506.3(FZD6): c.1531C> T (p.Arg511Cys) single nucleotide variant Pathogenic rs151339003 GRCh37 Chromosome 8, 104340634: 104340634
4 FZD6 NM_003506.3(FZD6): c.1531C> T (p.Arg511Cys) single nucleotide variant Pathogenic rs151339003 GRCh38 Chromosome 8, 103328406: 103328406
5 46;XY;inv(6)(p22q13)dn inversion Pathogenic
6 POGZ NM_015100.3(POGZ): c.2771delC (p.Pro924Argfs) deletion Pathogenic GRCh37 Chromosome 1, 151378740: 151378740
7 POGZ NM_015100.3(POGZ): c.2771delC (p.Pro924Argfs) deletion Pathogenic GRCh38 Chromosome 1, 151406264: 151406264
8 PKD1 NM_001009944.2(PKD1): c.226C> T (p.His76Tyr) single nucleotide variant Uncertain significance rs932577597 GRCh38 Chromosome 16, 2119368: 2119368
9 PKD1 NM_001009944.2(PKD1): c.226C> T (p.His76Tyr) single nucleotide variant Uncertain significance rs932577597 GRCh37 Chromosome 16, 2169369: 2169369
10 SETBP1 NM_015559.2(SETBP1): c.2614G> A (p.Gly872Arg) single nucleotide variant Likely pathogenic GRCh38 Chromosome 18, 44951954: 44951954
11 SETBP1 NM_015559.2(SETBP1): c.2614G> A (p.Gly872Arg) single nucleotide variant Likely pathogenic GRCh37 Chromosome 18, 42531919: 42531919
12 OFD1 NM_003611.2(OFD1): c.1999G> A (p.Ala667Thr) single nucleotide variant Uncertain significance GRCh37 Chromosome X, 13778578: 13778578
13 OFD1 NM_003611.2(OFD1): c.1999G> A (p.Ala667Thr) single nucleotide variant Uncertain significance GRCh38 Chromosome X, 13760459: 13760459

Expression for Nail Disease

Search GEO for disease gene expression data for Nail Disease.

Pathways for Nail Disease

GO Terms for Nail Disease

Cellular components related to Nail Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 8.8 EGFR KRAS TNFRSF1B

Biological processes related to Nail Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.33 EGFR PLCD1 TNFRSF1B
2 hair follicle development GO:0001942 8.96 EGFR FZD6
3 ERBB2 signaling pathway GO:0038128 8.62 EGFR KRAS

Sources for Nail Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....